$PFE @AlbertBourla may need to prep for a number of obesity setbacks in 2026 and beyond.
To start with Metsera Vesper 3. This is based dose escalation then monthly ..
it is clear to me will disappoint big in efficacy.
I wonder why
$MTSR didn’t push the dose > 1.2 mg but I believe this Halo-tag likely narrows therapeutic window.
In phase 1 -2024 Metsera reported SAD of up to 1.6 mg. Only mentioned efficacy of 1.2 mg. And then MAD was gone up to 1.2 mg only. No details of vomit that I could find.
In phase 2A they decided to escalate just up to 1.2 mg. Now they are testing monthly 4.8 mg.. will see how it goes. I doubt this will result in serious extra wt loss unless it triggers significant GI issues
- Also the oral peptide hype in extreme form.
They claim to have started po MEt 002 in Canada in 2024. No outcome reporting and no trace of it on clinical trials .Gov
Later claimed to be doing MET 024 that never progressed into humans and then CEO stated starting the same sc 097 in oral form but again no trace on clinical trial .gov
Metsera founded in 2022 on assets from a single UK academic lab and did licensing deal with a Korean company for enhancement of oral peptide delivery. No evidence of that system working and any pharma could have licensed it.
Oral peptide engineering is speciality of
$PTGX and little bit
$MRK through macrocyclic approach that is beyond Metsera reach and takes years to optimize and keep the molecules effective
I don’t see Pfizer coming any close to
$LLy or even
$NVO by 2023 based on these mediocre assets.